Due to new trends in medicine, pharma, biotech and medical-device companies are converging to develop the most-effective treatment options for patients.
Oncology and CNS are 2009's leading growth fields. The worldwide market value for oncology medicines is projected to top $50 billion for 2009. Annual double-digit growth will continue during the next decade, spurred by increasing usage of targeted therapies and new technologies for specialized areas. The $50+ billion CNS market will remain one of the largest and fastest-growing areas during upcoming years due to significant levels of unmet medical need. The product pipeline for CNS disorders is filled with a new generation of medicines with the ability to halt or reverse the progression of various diseases compared with current therapies that slow down advancement.
Pipelines from the top 15 therapeutic areas are presented in order determined by the total number of products awaiting approval and in clinical trials in the United States.
The lists for each therapeutic area detail:
-Phase of development